// App-Quantinova.ai

3153 : Mutations in CRBN and Other Cereblon Pathway Genes Are Only Associated with Acquired Resistance to Immunomodulatory Drugs in a Subset of Patients and Cell Line Models

Researchers

Presenter

  • Amy Barber

Principal Investigators

  • John R Jones

  • Harvey Che

  • Yann-Vai Le Bihan

  • Niels Weinhold

  • Cody Ashby

  • Brian A Walker

  • Christopher P. Wardell

  • Hannah Wang

  • Martin F. Kaiser

  • Graham H Jackson

  • Faith E. Davies

  • Rajesh Chopra

  • Gareth Morgan

  • Charlotte Pawlyn

Medical Centers

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • King's College Hosptial NHS Foundation Trust, London, United Kingdom

  • Dept. of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany

  • Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR

  • Pediatrics, Section of Hematology Oncology, Indiana University, Indianapolis, IN

  • University of Arkansas for Medical Sciences, Little Rock, AR

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Department of haematological sciences, Newcastle University, Newcastle-Upon-Tyne, United Kingdom,

  • Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY

Locations

  • United Kingdom

  • Germany

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Syndecan-1

Drug/Treatment

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • DMSO

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01554852

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved